Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more

Yes—an exploratory library of 71 inorganic coordination compounds showed how metallofragments could give fragment-based drug discovery access to molecular shapes that conventional organic fragments often underrepresent. The work is a proof of concept, not a drug discovery success story: a 2022 correction revised important activity results, and the study did not establish clinical efficacy or produce a medicine.

What makes this fragment library different?

Fragment-based drug discovery (FBDD) starts with relatively small molecules that bind to a biological target. Researchers can then grow, link, or merge promising “hits” into larger compounds for further study. Many conventional fragments are relatively flat. In contrast, this library began with inert metal coordination complexes—called metallofragments, or mFs—as three-dimensional core scaffolds, rather than adding a metal group to an existing organic inhibitor.

Morrison and colleagues reported 71 compounds organized into 13 structural classes, including sandwich, half-sandwich, and octahedral complexes. Compounds within a class shared a metal and core geometry but varied in functional groups or heterocycles. About 15% were purchased commercially; most were prepared using published methods. These figures describe the study’s library, not a catalog of compounds shown to be currently available. Read the 2020 Chemical Science paper.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

How much additional shape space did the researchers find?

The authors used normalized principal moment of inertia (PMI) analysis to compare molecular shapes. By the paper’s stated criterion, 55 of the 71 metallofragments (77%) counted as three-dimensional. For context, the paper cited prior analysis estimating that more than 75% of conventional organic fragments are predominantly one- or two-dimensional.

These are method-specific comparisons reported in the study—not a universal measurement of every fragment library, and not evidence that a three-dimensional fragment will necessarily bind well. The result supports a narrower point: the authors assembled a set with substantial 3D shape diversity that could complement more conventional fragments.

What targets did the researchers screen?

The library was screened against three proteins chosen to represent different areas of therapeutic research:

  • Influenza A PA endonuclease: an antiviral research target.
  • New Delhi metallo-β-lactamase-1 (NDM-1): an antibacterial research target.
  • Hsp90: an anticancer research target.

Selected compounds received follow-up testing, including IC50 measurements and thermal-shift assays. These are biochemical research results. They do not demonstrate safety or effectiveness in people, or show that a medicine is ready for patients.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

How did the 2022 correction change the reported hits?

The correction is essential context for interpreting the screening results. The authors found that DMSO stocks of some ferrocene-based compounds decomposed when exposed to light, leading to inaccurate inhibition measurements. When they retested with freshly prepared stocks, most of the originally reported highly active class A ferrocene compounds did not show significant inhibition against influenza PA endonuclease. A22 retained significant activity when freshly prepared and protected from light.

The authors said the class A activity data were affected, including results for other enzyme-target assays, IC50 values, and thermal-shift data. They also reported that retests of representative compounds from other classes largely reproduced earlier findings, with one exception: fragment F1 no longer showed activity on re-examination. The correction estimated an adjusted hit rate of about 28% (20 of 71) against PA endonuclease. That is the authors’ corrected estimate for this assay, not a clinical success rate or a general measure of metallofragment performance. Read the 2022 correction.

Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Support on Ko-Fi

What does the study establish—and what remains open?

The work establishes a proof-of-concept: inorganic coordination compounds can be assembled into a fragment library with varied three-dimensional shapes, and selected members can be screened against protein targets. The correction identifies stability and handling as important controls for interpreting activity in this kind of campaign.

It does not establish that this library led to an approved drug, that its compounds are clinically useful, or that 3D shape alone improves potency. The study’s contribution is a strategy and a set of assayable starting scaffolds for exploring underrepresented chemical space. The authors said in their correction that the core message—that metallofragments may serve as FBDD scaffolds occupying hard-to-access 3D chemical space—remains unchanged, while acknowledging the need to control for their distinctive handling challenges.

What’s actually slowing this PC down?

Pick the symptom - the matching free tool is one click away.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Quick Recap

Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.